Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06764615 · ClinicalTrials.gov registry record · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
A Phase 2 study of Ulcerative Colitis and Crohn's Disease, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
- 16
- Study locations
NCT06764615 is a Phase 2 study of Ulcerative Colitis and Crohn's Disease that is actively recruiting participants, run by Takeda. The registered enrollment target is 183 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (91% lower). The trial reports 16 study locations across 10 states.
The verdict
NCT06764615, a Phase 2 study of Ulcerative Colitis and Crohn's Disease, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
- 16
- Study locations
Study Summary
Crohn's Disease and Ulcerative Colitis are two types of inflammatory bowel disease (IBD), which is a serious, long-term condition in the gut (intestine) that can cause pain and swelling (inflammation) in the bowel. TAK-279 is a medicine which helps to block inflammation. This study is an extension of the parent studies, TAK-279-CD-2001 (NCT06233461) and TAK-279-UC-2001 (NCT06254950). This means that participants who responded to treatment with TAK-279 in either of the parent studies may be able to continue to benefit from the treatment in this study. The main aim of this study is to find out how safe TAK-279 is for long term use and to check if it reduces bowel inflammation and symptoms when used for a longer period of time in adults with moderately to severely active UC or CD. The participants will be treated with TAK-279 for up to 2 years (108 weeks). During the study, participants will visit their study clinic 11 times.
Conditions Studied
Interventions
- DRUG Zasocitinib
Study Locations (16)
Other
- Hepato-Gastroenterologie HK s.r.o. - Hradec Králové
- Pannonia Maganorvosi Centrum - Budapest
- Centrum Medyczne MedykSp. z o.o. Sp. K. - Lublin
- Twoja Przychodnia - Szczecinskie Centrum Medyczne - Szczecin
- WIP Warsaw IBD Point Profesor Kierkus - Warsaw
- Endomed - Košice
Guangdong
- The First Affiliated Hospital of Sun Yat-sen University - Guangdong
- The Sixth Affiliated Hospital of Sun Yat-sen University - Guangzhou
Maryland
- Woodholme Gastroenterology Associates - Glen Burnie
Texas
- Tyler Research Institute, LLC - Tyler
Chongqing Municipality
- Chongqing General Hospital - Chongqing
Shanghai Municipality
- Renji Hospital Shanghai Jiaotong University School of Medicine - Shanghai
North Brabant
- St. Antonius Ziekenhuis - Tilburg
Kuyavian-Pomeranian Voivodeship
- Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj - Torun
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2029-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06764615
The ClinicalTrials.gov registry entry for NCT06764615 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (91% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Zasocitinib is the first listed.
NCT06764615 reports 16 study locations spanning 10 distinct geographic areas - top geographies include Other, Guangdong, Maryland.
Frequently Asked Questions
What is clinical trial NCT06764615 about?
NCT06764615 is a clinical study titled "A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)". Crohn's Disease and Ulcerative Colitis are two types of inflammatory bowel disease (IBD), which is a serious, long-term condition in the gut (intestine) that can cause pain and swelling (inflammation) in the bowel. TAK-279 is a medicine which helps to block inflammation. This study is an extension ...
What is the current status of trial NCT06764615?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2025-05-28. Estimated completion is 2029-12-30.
What conditions does trial NCT06764615 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Crohn's Disease.
What interventions are being tested in trial NCT06764615?
The interventions under investigation include: Zasocitinib (DRUG).
Who is sponsoring clinical trial NCT06764615?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06764615 being conducted?
This trial has 16 study locations across Maryland, Texas, Chongqing Municipality, Guangdong, Shanghai Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.